Oxford Biomedica (LON:OXB) Stock Crosses Below 200 Day Moving Average – Time to Sell?

Oxford Biomedica plc (LON:OXB)’s stock price crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of GBX 570.92 and traded as low as GBX 509. Oxford Biomedica shares last traded at GBX 509.67, with a volume of 347,118 shares trading hands.

Analysts Set New Price Targets

Several equities analysts have weighed in on OXB shares. Royal Bank Of Canada reaffirmed an “outperform” rating and set a GBX 900 price target on shares of Oxford Biomedica in a report on Tuesday, September 1st. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 595 price objective on shares of Oxford Biomedica in a research report on Wednesday, September 2nd. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of GBX 580.85.

Oxford Biomedica Stock Up 6.9%

The firm’s 50 day simple moving average is GBX 498.97 and its 200 day simple moving average is GBX 570.73. The company has a market cap of £658.50 million, a price-to-earnings ratio of -20.21 and a beta of 1.09. The company has a quick ratio of 1.67, a current ratio of 2.21 and a debt-to-equity ratio of 273.08.

Oxford Biomedica (LON:OXB) last released its earnings results on Wednesday, September 23rd. The biopharmaceutical company reported GBX (30.39) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative return on equity of 54.51% and a negative net margin of 23.23%. Sell-side analysts anticipate that Oxford Biomedica plc will post -31.0799998 EPS for the current fiscal year.

Insiders Place Their Bets

In other Oxford Biomedica news, insider Roch Doliveux bought 20,250 shares of the firm’s stock in a transaction that occurred on Wednesday, September 23rd. The stock was acquired at an average price of GBX 505 per share, with a total value of £102,262.50. Insiders own 43.30% of the company’s stock.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.